Charles Andrews
Internal Medicine · Newport Beach, CANPI 1750345955
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 375 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $2,220 and has fallen 71.9% since, to $625 in 2022. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 375 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Pfizer$665
- AstraZeneca$491
- Lilly USA, LLC$489
- Boehringer Ingelheim$450
- Amgen$436
- plus $2K from 23 others
What the payments were for
- Food & beverage$6,095100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 116 | $1,371 |
| Pfizer | 38 | $665 |
| AstraZeneca | 27 | $491 |
| Lilly USA, LLC | 32 | $489 |
| Boehringer Ingelheim | 20 | $450 |
| Amgen | 18 | $436 |
| AbbVie(2 entities) | 18 | $354 |
| GSK | 14 | $286 |
| Johnson & Johnson | 18 | $268 |
| Vanda Pharmaceuticals Inc. | 8 | $190 |
| Novartis | 9 | $153 |
| Esperion Therapeutics, Inc. | 8 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $125 |
| Amarin Pharma, Inc. | 5 | $111 |
| Bausch Health US, LLC | 6 | $102 |
| Eisai Inc. | 4 | $67 |
| Merck | 4 | $57 |
| Astellas Pharma US Inc | 3 | $57 |
| Genentech USA, Inc. | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Radius Health, Inc. | 1 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Alfasigma USA, Inc. | 2 | $31 |
| Bard Peripheral Vascular, Inc. | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Bayer | 1 | $20 |
| Assertio Therapeutics, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$6,119 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Newport Beach
- Tung NgoNewport Beach$4.9M
- Andrew ChengSouth San Francisco$55.1M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.